|
1）Hauschka PV, Lian JB, Gallop PM. Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci U S A. 1975; 72: 3925-9
|
|
|
|
2）Kameda T, Miyazawa K, Mori Y, et al. Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast apotosis. Biochem Biophys Res Commun. 1996; 220: 515-9
|
|
|
|
|
|
3）Hara K, Akiyama Y, Nakamura T, et al. The inhibitory effects of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. Bone. 1995; 16: 179-84
|
|
|
|
|
|
4）Booth SL, Tucker KL, Chen H, et al. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr. 2000; 71: 1201-8
|
|
|
|
|
|
5）Vergnaud P, Garnero P, Meunier PJ, et al. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab. 1997; 82: 719-24
|
|
|
|
|
|
6）Cheung AM, Tile L, Lee Y, et al. Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial. PLoS Med. 2008; 5: e196
|
|
|
|
|
|
7）Shiraki M, Shiraki Y, Aoki C, et al. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 2000; 15: 515-21
|
|
|
|
|
|
8）Knapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int. 2007; 18: 963-72
|
|
|
|
|
|
9）Cockayne S, Adamson J, Lanham-New S, et al. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2006; 166: 1256-61
|
|
|
|
|
|
10）Kohlmeier M, Saupe J, Shearer MJ, et al. Bone health of adult hemodialysis patients is related to vitamin K status. Kidney Int. 1997; 51: 1218-21
|
|
|
|
|
|
11）Luo G, Ducy P, Mckee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997; 386: 78-81
|
|
|
|
|
|
12）Zebboudj AF, Imura M, Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem. 2002; 277: 4388-94
|
|
|
|
|
|
13）Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001; 21: 1998-2003
|
|
|
|
|
|
14）Jie KS, Bots ML, Vermeer C, et al. Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population-based study. Atherosclerosis. 1995; 1: 117-23
|
|
|
|
|
|
15）Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004; 134: 3100-5
|
|
|
|
|
|
16）Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost. 2008; 100: 593-603
|
|
|
|
|
|
17）Westenfeld R, Krueger T, Schlieper G, et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2012; 59: 186-95
|
|
|
|
|
|
18）Schurgers LJ, Barreto DV, Barreto FC, et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol. 2010; 5: 568-75
|
|
|
|
|
|
19）Schlieper G, Westenfeld R, Kruger T, et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol. 2011; 22: 387-95
|
|
|
|
|
|
20）Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial. 2002; 15: 172-86
|
|
|
|
|
|
21）Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012; 27: 1580-4
|
|
|
|
|
|
22）Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010; 77: 1098-106
|
|
|
|
|
|
23）Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007; 130: 456-69
|
|
|
|
|
|
24）Ferron M, Hinoi E, Karsenty G, et al. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A. 2008; 105: 5266-70
|
|
|
|
|
|
25）Yoshida M, Booth SL, Meigs JB, et al. Phylloquinone intake, insulin sensitivity, and glycemic status in men and women. Am J Clin Nutr. 2008; 88: 210-5
|
|
|
|
|
|
26）Nakashima A, Yorioka N, Doi S, et al. Radial bone mineral density in hemodialysis patients with adynamic bone disease. Int J Artif Organs. 2003; 26: 200-4
|
|
|
|
|
|
27）Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000; 36: 1115-21
|
|
|
|
|
|
28）Kurz P, Monier-Faugere MC, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994; 46: 855-61
|
|
|
|
|
|
29）Nakashima A, Yorioka N, Doi S, et al. Effect of Vitamin K2 in hemodialysis patients with low serum parathyroid hormone levels. Bone. 2004; 34: 579-83
|
|
|
|
|
|
30）Ochiai M, Nakashima A, Takasugi N, et al. Vitamin K2 alters bone metabolism markers in hemodialysis patients with a low serum parathyroid hormone level. Nephron Clin Pract. 2010; 117: 15-9
|
|
|
|
|